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Opinion
Open access under CC BY-NC-ND license.Alternatives to antibiotics are urgently needed in animal
agriculture. The form these alternatives should take pre-
sents a complex problem due to the various uses of
antibiotics in animal agriculture, including disease treat-
ment, disease prevention, and growth promotion, and to
the relative contribution of these uses to the antibiotic
resistance problem. Numerous antibiotic alternatives,
such as pre- and probiotics, have been proposed but show
variable success. This is because a fundamental under-
standing of how antibiotics improve feed efficiency is
lacking, and because an individual alternative is unlikely
to embody all of the performance-enhancing functions of
antibiotics. High-throughput technologies need to be
applied to better understand the problem, and informed
combinations of alternatives, including vaccines, need to
be considered.
Introduction: the need for antibiotic alternatives
Antibiotics have long been used for treating disease, pre-
venting disease, and improving feed efficiency in conven-
tional livestock and poultry production. Their use was
implemented in the 1950s as a way to meet the increasing
demand for food. Antibiotics given to pigs were estimated
to save as much as 20% of feed per pound of weight gain [1].
Whether the same performance enhancement continues in
the present remains unclear [2]. Concurrent with antibi-
otic use, antibiotic-resistant bacteria were isolated from
animals receiving antibiotics from the earliest days. Con-
cerns quickly arose about the development of resistant
pathogens associated with animal and human diseases, as
well as increases in the antibiotic resistance gene pool in
commensal bacteria, but the risk was outweighed by the
benefits of reduced cost to the industry [3]. In addition to
improving feed efficiency, antibiotics in agricultural ani-
mals are used to improve animal welfare, and so there
must be a balance between antibiotic use and preserving
antibiotic efficacy for both human and animal health.
Sixty years later, the debate continues in the USA and
abroad. Concerns over the spread of antibiotic-resistance
genes to human and animal pathogens continue to drive
the debate [4].DOI of original article: http://dx.doi.org/10.1016/j.tim.2012.11.002.
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growth-promoting antibiotics, and the practice in the USA
is under increasing regulatory and political scrutiny. The
Center for Veterinary Medicine of the US Food and Drug
Administration (FDA) recently issued a ‘Guidance for In-
dustry’ that describes requirements for label claims and
recommended restrictions on uses of antibiotics in food-
producing animals [5]. This document outlines voluntary
limitations on the use of antibiotics based on the risk
assessment of resistance development and on the impor-
tance of a given antibiotic to human therapy. The two
guiding themes for the risk assessment were that anti-
biotics should only be used for prevention, control, and
treatment of specific animal diseases and a requirement
for veterinarian involvement in the decision to use anti-
biotics. Although the new FDA guidance allows antibiotic
use in food-producing animals to control specific diseases,
the use of antibiotics for growth promotion, increased
performance, and improved feed efficiency will no longer
be permitted. Additionally, certain antibiotics of critical
importance, such as third-generation cephalosporins, are
likely to be restricted to human use in the near future even
if they are important for animal disease treatment [6]. This
is in part because of the demonstrated potential for veteri-
nary antibiotics (e.g., tylosin) to coselect for resistance to
antibiotics of human importance (e.g., vancomycin) [7]. It is
important to recognize that the FDA guidelines may lead
to more sickness and to an increased demand for thera-
peutic antibiotic treatment in livestock (as was seen in
Denmark [8]). Alternatives to growth-promoting antibio-
tics are therefore only a fraction of the problem; we also
need alternatives for disease prevention and control, and
treatment of animals (Box 1).
Challenges of antibiotic alternatives
Alternatives to antibiotics in food-producing animals are
urgently needed but present a difficult problem in part
because of the complexity of the gastrointestinal (GI) eco-
system. The GI tract is an intricate organization of epithelial
cells (the mucosal barrier), the mucosal immune system,
and microbiota. The epithelium with its mucus layer sepa-
rates the microbiota, pathogens, and unfavorable environ-
mental conditions from the host, and is also the main site of
nutrient absorption. The GI microbiota competes with in-
testinal pathogens for nutrients and binding sites, producestim.2012.11.001 Trends in Microbiology, March 2013, Vol. 21, No. 3
Box 1. Defining commonly misunderstood concepts
Investigating alternatives to antibiotics in agriculture requires an
understanding of the language of antibiotic use in agriculture.
Below are the definitions of several concepts that are often used
imprecisely.
Subtherapeutic vs. subinhibitory
Subtherapeutic is not synonymous with subinhibitory. A subther-
apeutic dose of an antibiotic is an amount usually given for
performance enhancement and is less than the amount used to
treat disease (therapeutic dose). Subtherapeutic is defined by the
effect of an antibiotic on the animal. By contrast, a subinhibitory
dose of antibiotic is less than the minimal inhibitory concentration,
which is defined as the concentration necessary for inhibition of
bacterial growth under specific in vitro conditions prescribed by the
Clinical Laboratory Standards Institute. Subinhibitory is defined by
the effect of an antibiotic on bacteria.
Animal pathogen reduction vs. human pathogen reduction among
animal commensal bacteria
Reducing the prevalence of pathogens in the animal gut microbiota
can mean two things: inhibiting potential pathogens of the animal
and inhibiting potential foodborne pathogens that inhabit the
animal’s gut. The former but not the latter is considered when
discussing alternatives for antibiotics because foodborne pathogens
are not targeted by antibiotics administered to animals.
Growth promotion vs. treatment, prevention, and control of specific
diseases
Antimicrobial growth promoters are antibacterial compounds that
are added to animal feed or water in subtherapeutic amounts for
extended periods of time to enhance production performance of
agricultural animals as measured by increased feed efficiency (ratio
of feed input to weight gain). This use of antibiotics for growth
promotion is prohibited in the European Union and the US FDA has
proposed restrictions. Animals are susceptible to bacterial diseases,
however, and so therapeutic doses of antibiotics over shorter
timescales to treat and control specific bacterial diseases are
warranted and allowed.
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and influences immune maturation. A healthy microbiota
filled with beneficial microbes is certainly important to
animal health, but both a healthy microbiota and its con-
verse, dysbiosis, are poorly defined. Metagenomics, meta-
transcriptomics, and other ‘omics’ technologies provide an
opportunity for defining the microbes and microbial activi-
ties that compose and maintain a healthy microbiota [9,10].
Of particular importance is the homeostasis between a
healthy microbiota and the immune system because the
microbiota modulates innate immune responses to prevent
barrier dysfunction and regulates the function of adaptive
immune mediators [11–13]. In turn, the host exerts immune
tolerance, moderates inflammation, and competes with the
microbiota for nutrients, all of which incur an energy cost.
Knowledge about the mechanism of how antibiotics en-
hance animal growth is important to the development of
viable alternatives. How antibiotics increase performance is
not clear, but possible mechanisms may include a reduction
in total bacterial load, suppression of pathogens, thinning of
the mucosal layer, and direct modulation of the immune
system [14,15] (Figure 1a). Some gut bacteria may decrease
the energy cost to the immune system, yielding surplus
calories for weight gain. Additional growth-promoting
effects of antibiotics could include increased nutrient ab-
sorption by the host or bacterial community remodeling infavor of non-antagonistic or beneficial bacteria and func-
tions [16,17]. Defining the effect of antibiotics and alterna-
tives on the host and its microbiota will facilitate the
development of efficacious solutions.
The different potential mechanisms of antibiotic growth
promotion beget different alternatives (Figure 1b). Using
targeted approaches to reduce the carriage of specific
pathogens or to alter the host immune response will be
important to prevent or reduce disease burden and posi-
tively influence growth performance without the collateral
effects of antibiotic treatment [18]. If the mechanism is
dependent on the microbiota or its interaction with the
immune system, then feed additives such as pre- or pro-
biotics are appropriate. If the mechanism of growth pro-
motion is via disease prevention or reduction, then the
most appropriate alternatives would be vaccines or health-
promoting pre- or probiotics. Below we will discuss some of
the advantages and disadvantages of various alternatives
to antibiotics in agricultural animals.
Feed additives
The nutritional components of animal feed are continually
adjusted to optimize the effects on animal health and
growth while being largely dependent on feed input costs.
Dietary supplementation may also include prebiotics, pro-
biotics, and organic acids. Prebiotics are selectively fer-
mented components of feed (either inherent or added) that
modulate the gut microbiota to benefit host health, such as
the competitive exclusion of pathogens or the stimulation
of health-promoting metabolites [19]. Primary examples of
prebiotics include dietary fibers and oligosaccharides. Like
prebiotics, in-feed organic acids can be inherent or added,
and they function by decreasing the pH of an environment,
limiting feed spoilage, and resulting in lower pathogen
survival in the gut [20]. Organic acid delivery ranges from
the addition of a single component such as lactic acid to
complex blends created by fermentation. Probiotics confer
benefits analogous to prebiotics but are living cells such as
Lactobacillus, Streptococcus, Bifidobacterium, Bacillus,
and yeasts [21,22]. Traits important to a probiotic strain
include being nonpathogenic, resistance to stomach acids
and bile, having the potential to colonize the host, produc-
tion of nutrients, being free of antibiotic resistance genes or
having reduced gene transfer functions, and antagonism of
pathogens.
The potential for the above additives to replace antibio-
tics is well established, and numerous pre- and probiotic
products are commercially available and in active use [23–
25]. However, the true efficacy of pre- and probiotics in
agricultural animals remains unclear because of inconsis-
tent experimental results [26,27]. Explanations for the dis-
parities between studies include differences in experimental
conditions, animal age, genetics, and health status. Addi-
tionally, the inconsistent results could be attributed to a lack
of understanding of the mechanism of action for either pre-
or probiotics, as well as unknown interactions among these
products, the host, and the GI microbiota. For example,
there have been studies that quantify some aspects of the
GI microbiota in response to probiotics [28]. However, the
methods applied to the microbial community in those stud-
ies have not been able to fully characterize the community,115
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Figure 1. Antibiotics and their alternatives have many effects on the gut microbiome. Shown is a schematic representation of a longitudinal section of the gut, with the
lumen in the center (brown shading), surrounded by the mucosa (epithelium is dark pink, lamina propria is light pink) containing immune cells (red and green nucleated
ovals). (a) Antibiotics exert positive (arrows) and negative (bars) effects on a variety of factors in the gut: they can inhibit the mucosal immune system (green nucleated
cells), inhibit pathogens (yellow rods), or modulate the microbiota by stimulating some members (red cocci) while inhibiting others (dark blue cocci), or all of the above. (b)
A potentiated prebiotic is presented as an example of mixed additives, an approach that might be the most comprehensive alternative to antibiotics because each separate
component (i.e., anti-inflammatory, prebiotic, and vaccine) replicates a different effect conferred by the antibiotic.
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vice versa) largely unknown. Thorough study of the changes
in the microbiota and host responses to feed additives using
next-generation sequencing technologies combined with
systems biology approaches will greatly advance this field.
Phage therapy
An additional antibiotic alternative that has enjoyed
renewed traction is bacteriophage (phage) therapy. Phage
therapy involves the use of bacterial viruses (phages) to
attack a specific bacterium or narrow group of bacteria
with the advantage over antibiotics being that autochtho-
nous bacteria are unharmed and no dysbiosis occurs [29].
The success of phage therapy is dependent on numerous
factors. Phages have a narrow bacterial host range and do
not target multiple bacterial pathogens, so the efficient use
of phage therapy requires the identification of the patho-
gen or at least a high suspicion of their presence. It is most
efficacious when the bacteria being treated are readily
accessible, such as the historical treatment of dysentery
[29] or the modern treatment of burn wounds [30]. In
addition to being accessible, the numbers of target bacteria
need to be high. Experiments using lytic phages to counter
the foodborne pathogen Salmonella enterica serovar
Typhimurium in chickens [31] and pigs [32] have reduced
but not eliminated the Salmonella load. One confounding
factor was that the inoculated phage only persisted in the116gut as long as Salmonella remained abundant [31]. Also,
therapy is most effective when phages are administered
soon after bacterial infection. The seminal work of H.W.
Smith and colleagues showed that K1 phages injected
intramuscularly are 100% effective at curing mice of
Escherichia coli O18ac:K1:H7 ColV+ infections when
injected immediately following bacterial inoculation [33].
The efficacy of the phage treatment was lost, however,
when phages were administered 16 h after infection, thus
limiting phage therapy to prophylactic or immediate-treat-
ment situations. Another reason why the efficacy of phage
therapy needs constant monitoring is that the host im-
mune response may neutralize phages (although this prob-
ably only occurs after repeated treatment) [34]. Finally,
concern over the target bacteria becoming resistant to the
phage often necessitates the generation and administra-
tion of phage cocktails [29]. The somewhat boutique nature
of phage therapy – requiring specific, accessible, and abun-
dant target bacteria and administration soon after infec-
tion – continues to challenge its adoption as a viable
antibiotic alternative in Western countries [35].
In addition to the technical challenges, the biological
and evolutionary consequences of phage therapy need to be
considered. For example, it is important to avoid temperate
phages for therapeutic application because of the potential
for transfer of virulence or antibiotic resistance genes from
the phage to the host bacterium, although even obligate
Opinion Trends in Microbiology March 2013, Vol. 21, No. 3lytic phages harbor genes of unknown function that could
also result in undesired gene transfer [36]. One way to
avoid this is the use of purified phage gene products such as
lysins to selectively kill target bacteria. Phage lysins could
be applied to a bacterial infection, particularly on an
accessible mucosal surface, and attenuate the infection
by lysing the bacteria from without [37]. The discovery
and development of novel phage-derived therapeutics
could benefit by the application of functional metagenomic
analyses, which are a high-throughput way of bioprospect-
ing for functions of interest such as phage lysins [38].
Vaccines
Vaccines are an underappreciated antibiotic alternative
despite the availability of many effective vaccines and a
general understanding of vaccine immunology. This is
compared with other proposed alternatives such as pre-
biotics or probiotics where limited mechanistic information
is wrought with highly variable efficacy. Based on the more
comprehensive understanding of immune responses and
protection, vaccines should be a promising antibiotic alter-
native for reducing the burden of animal diseases and
human pathogens in food-producing animals. Additionally,
it is important to note that vaccination could also reduce
the use of therapeutic antibiotics because of the reduction
in clinical infections. As an example, vaccination against
the swine pathogen Lawsonia intracellularis reduced the
need for therapeutic oxytetracycline administration in
Danish pigs [39]. Similar decreased need for therapeutic
antibiotics might also be anticipated following widespread
adoption of vaccines for other pathogens.
Broad discussion of all possible vaccines targeting animal
or foodborne pathogens is beyond the scope of this manu-
script due to the specificity of host–antigen interactions. We
will therefore consider potential vaccines for one example –
the immediate post-weaning period in swine – because it is
likely to be a time during which growth-promoting antibio-
tics are most effective at bacterial disease reduction [40].
Major enteric pathogens that cause disease problems and
production losses during the post-weaning and later periods
in swine include enterotoxigenic and shigatoxigenic E. coli
(the causative agent of post-weaning diarrhea and edema
disease), Brachyspira hyodysenteriae (the causative agent of
swine dysentery), L. intracellularis (the causative agent of
porcine proliferative enteropathy), and Salmonella enterica
serovar Choleraesuis (the causative agent of systemic sal-
monellosis in swine). Oral vaccination of weaned pigs with
live attenuated bacterial vaccines is thought to be the most
effective approach for reducing enteric diseases in swine.
Live oral vaccination is the strategy for the commercial
vaccines available for the reduction of L. intracellularis
[41] and S. Choleraesuis [42] -associated diseases, but the
promise of this approach for swine pathogenic E. coli has not
progressed to commercial products (e.g., [43]). Efficacious
parenterally administered toxoid or adhesin subunit vac-
cines against experimental E. coli infections have been
reported but have not been commercialized (e.g., [44]).
Experimental vaccines against B. hyodysenteriae have been
reported as subunit vaccines as well as whole cell bacterins,
but evaluation and efficacy data are limited (e.g., [45]).
Development of effective vaccines to prevent disease andassociated production losses during the post-weaning period
should be a priority in the search for replacements for
growth-promoting antibiotics. Acceptance and widespread
use of vaccinations as alternatives to antibiotics will depend
on cost and ease of use. Cost comparisons may be difficult,
but administration of live oral vaccines in feed or water
could be comparable to administration of antibiotics by
these routes.
Mixing additives: potentiated probiotics and synbiotics
Combinations of antibiotic alternatives hold the promise of
potentiating each other’s efficacy and duplicating the effect
of in-feed antibiotics (Figure 1b). The term potentiated
probiotics refers to such combinations of probiotics with
other additives (e.g., vaccines or organic acids) with the
goal of synergistically increasing the effect of the probiotic
[23,46]. For instance, it is possible that a prebiotic that only
confers gastrointestinal health benefits could support the
growth of, and be simultaneously delivered with, a probi-
otic that competitively excludes a potential pathogen. The
most common pairing that has been tested is prebiotics
with probiotics, and this combination is termed synbiotic.
Like studies utilizing probiotics or prebiotics individually,
synbiotic studies have found inconsistent results, with
some studies reporting gains in animal performance or
decreases in food borne pathogens (reviewed in [26]), but
others have not (e.g., [28]). Other combinations such as
probiotics and vaccines for food safety have rarely been
tested, but a combination of competitive exclusion cultures
and a Salmonella vaccine resulted in a greater protective
effect than either treatment alone [47]. Another attempted
approach was a probiotic E. coli that produced a microcin
that can inhibit growth of Salmonella, but in vivo experi-
ments were unsuccessful at reducing Salmonella shedding
[48]. A better understanding of the effects and mechanisms
of action of the various components, as enabled by high-
throughput sequencing, will allow for more rational poten-
tiated probiotic designs, guiding the selection of antibiotic
alternatives that best complement each other and best
replicate the effect of growth-promoting antibiotics.
Concluding remarks
No ‘magic bullet’ alternative exists to cover the spectra of
antibiotic classes and antibiotic uses in agricultural ani-
mals. Alternatives such as vaccines or bacteriophages, al-
though limited to the control of specific bacterial species or
strains, benefit from not having antibiotic side effects of
perturbing entire microbial populations. Vaccine combina-
tions or phage gene products would yield a broader bacterial
target range. Interdisciplinary translational research em-
phasizing all three components of host health – gut micro-
biota, intestinal physiology, and immunology – holds
promise for discovering antibiotic alternatives (Box 2). This
approach is now feasible through new technologies allowing
integrated research to simultaneously examine genomes,
metagenomes, transcriptomes, and proteomes. As with any
animal management approach, a significant challenge for
antibiotic alternatives will be low cost per animal, and this
challenge should diminish as demand increases. Despite the
obstacles, many alternatives have been proposed and pro-
ductive collaborations among biochemists, microbiologists,117
Box 2. Considering alternatives in the context of host–
microbe evolution
The effect of antibiotics and their alternatives on an animal and its
gut microbiota is usually examined before, during, and after
antibiotic administration. However, evolutionary factors are worthy
of consideration, such as the vertical transmission of the hologen-
ome (the combined genetic information of the host and its
microbes). It is important to assess the impact of any antibiotic
treatment or alternative in terms of future outcomes (e.g., sub-
sequent generations) in addition to immediate outcomes (e.g.,
disease prevention, increased weight gain, etc.).
The homeostatic symbiotic relationship between hosts and their
microbiota is an ancient product of a long co-evolutionary process,
and it appears to be vertically transmitted [49–51]. This vertical
transmission is tied to evolution because although selection acts on
individual genes (both host and microbial), gene selection is
influenced by ecological forces such as interactions among
microbes and host factors [52]. Host genetics, by shaping the
microbial community [51], and ecological forces such as antibiotics
and their alternatives combine to influence host–microbial interac-
tions. One theory of evolution, the hologenome theory, is notable in
its inclusion of both the host and its microbial community. The
hologenome theory considers the holobiont (the host and its
microbiota), acting in concert with its total combined genetic
information (the hologenome), as a unit of selection in evolution
[49].
In the context of the hologenome theory of evolution, it is possible
that some of the desired effects of antibiotics are perhaps being
vertically transmitted in the microbiota or the host or both, and
therefore maintained by the holobiont without continued antibiotic
application. The influence of modern production practices, such as
directed breeding, on this vertical transmission is unclear. It is
additionally unknown whether or not the relatively short history of
antibiotic use is sufficient time for an evolutionary change to be
detected, but it is tempting to speculate that at some point the
holobiont could inherit the benefits of antibiotic treatment and that
these benefits would continue in the absence of antibiotics. If that is
the case, then the search for alternatives in agriculture animals
should focus on maintaining the evolutionary changes brought
about by antibiotics in addition to replicating other effects of
antibiotics.
Opinion Trends in Microbiology March 2013, Vol. 21, No. 3immunologists, nutritionists, veterinarians, and animal
care managers capitalizing on the latest technologies will
define mechanisms and lead to effective solutions.
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